Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-07-26
1993-10-26
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424650, 424653, 514 29, 514 37, 514 39, 514 41, 514154, 514163, 514192, 514198, 514199, 514200, 514390, 514503, 514926, 514927, A61K 31415, A61K 3324, A61K 3170, A61K 3165, A61K 3161, A61K 3143, A61K 31545, A61K 3129
Patent
active
052566846
ABSTRACT:
Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.
REFERENCES:
patent: 3247051 (1966-04-01), Leebrick
patent: 4016268 (1977-04-01), Goldenberg et al.
patent: 4153685 (1979-05-01), Serfontein
McGraw-Hill, "Dictionary of Scientific and Technical Terms, Second Ed." (1978), p. 665.
Stedman's Medical Dictionary, 24th Ed. (1982) p. 577.
Heraud et al., "Therapeutic trial of an association of an insoluble bismuth salt and a Karaya gum in gastro-intestinal pathology", Lille Medical, 3rd Series vol. XIV, No. 6, supplement, pp. 677-679 (1969).
Abstract: "Histological Improvement of Active Chronic Gastritis in Patients Treated with De-Nol", presented at a meeting of the Gastroenterological Society of Australia, Mar. 11-14, 1984, Melbourne, Australia.
M. B. Skirrow, "Report on the Session" in Campylobacter 11, Proceedings of the Second International Workshop on Campylobacter Infections (London, 1983; Public Health Laboratory Service; Pearson, Skirrow et al., editors), pp. 5-10.
Marshall and Warren, "Spiral bacteria in the human stomach: a common finding in patients with gastritis and duodenal ulcer" in: Campylobacter II, Proceedings of the Second International Workhip on Campylobacter Infections (London, 1983; Public Health Laboratory Service; Pearson, Skirrow et al., editors), pp. 11-12.
Gisselbrecht et al., "Treatment of constipation and colitis by the association of bismuth subnitrate and Karaya gum", Lyon Med., 223(18), pp. 951-958 (1970).
Navarranne, "Treatment of spasmodic and psychosomatic colopathies by a cicatrisant, antiseptic and anxiolytic medication combination", Therapie, XXII, pp. 419-426 (1967).
Colson, "The treatment of chronic colitis and colpathies by a new association of bismuth, mucilage, oxyquinoline and meprobamate", Revue des corps de sante des Armees, 7(2), pp. 319-334 (1966).
A. Freedberg, et al., "The Presence of Spirochetes in Human Gastric Mucosa", 7 American Journal of Digestive Diseases 443-445 (1940).
M. Goldenberg, et al., "Protective Effects of Pepto-Bismol Liquid on the Gastric Mucosa of Rats", 69 Gastroenterology 636-640 (1975).
M. Steinhoff, et al., "Bismuth Subsalicylate Therapy of Viral Gastroenteritis", 78 Gastroenterology 1495-1499 (1980).
M. Blaser, et al., "Campylobacter Enteritis", 305 New England Journal of Medicine 1444-1452 (1981).
J. Koo, et al., "Selective Coating of Gastric Ulcer by Tripotassium Dicitrato Bismuthate in the Rat", 82 Gastroenterology 864-870 (1982).
M. Gregory, "The Effect of Tri-potassium Di-citrato Bismuthate on the Duodenal Mucosa During Ulceration" 62 S.A. Medical Journal 52-55 (1982).
J. Warren, "Unidentified Curved Bacilli on Gastric Epithelium in Active Chronic Gastitis" 1 Lancet 1273 (1983).
B. Marshall, "Unidentified Curved Bacilli on Gastric Epithelium in Active Chronic Gastitis" 1 Lancet 1273-1275 (1983).
Z. Zheng, et al., "A Double-blind Short-term Clinical Trial of the Effect of Furazolidone in Peptic Ulcer", 23 Chinese J. of Int. Medicine 195-197 (1984).
C. McNulty, et al., "Spiral Bacteria of the Gastric Antrum" 1 Lancet 1068 (1984).
B. Marshall, et al., "Unidentified Curved Bacilli in the Stomach of Patients with Gastritis and Peptic Ulceration" 1 Lancet 1311-1315 (1984).
M. Langenberg, et al., "Campylobacter-like Organisms in the Stomach of Patients and Healthy Individuals" 1 Lancet 1348 (1984).
R. Burnett, et al., "Campylobacter-like Organisms in the Stomach of Patients and Healthy Individuals" 1 Lancet 1349 (1984).
B. Marshall, et al., "Pyloric Campylobacter Serology" 2 Lancet 281 (1984).
A. McLean, et al., "Microbes, Peptic Ulcer and Relapse Rates with Different Drugs", 2 Lancet 525-526 (1984).
B. Marshall, et al., "Pyloric Campylobacter Infection and Gastroduodenal Disease" 142 Medical Journal of Australia 439-444 (1985).
Z. Zheng, et al., "Bouble-blind Short-term Trial of Furazolidone in Peptic Ulcer" 1 Lancet 1048-1049 (1985).
C. McNulty, et al., "Rapid Diagnosis of Campylobacter-Associated Gastrtis" 1 Lancet 1443-1444 (1985).
K. I. Shirokova, et al., "The Use of Metronidazole in Treatment of Patients with Ulcerative Disease", 59 Klin. Med.-(Mosk) 48-50 (1981).
Z. T. Zheng, et al., "Treatment of Gastrointestinal Ulcer by Furazolidone", 2 Chinese J. of Digestion 131-133 (1982).
L. Lu, et al., "Effect of Furaxon and It Analogs on Gastrointestinal Propulsion in Mice", 15 Beijing Yixueyuan Xuebao 185-187 (1983).
B. E. He, et al., "Cytoprotection of Furazolidone in Resistant-Soakage Gastric Ulcers in Rats", 4 Jinau Liyi Xuebao 55-59 (1984).
S. Zhang. et al., "Protective Effects of Furazolidone and Some Commonly Used Antiulcer Drugs on Several Gastric Ulcer Models in Rats", 19 Yaoxue Xuebao 5-11 (1984).
Physicians Desk Reference for Nonprescription Drugs 646 (1985).
B. J. Marshall, "Perspective-Campylobacter pyloridis and Gastritis" 153 J. of Infectious Diseases 650-657 (1986).
"Bismosal, Mixture Cholera Infantum, Norwich" (Advertisement) (1918).
"Stomach Upset" (Advertisement) (1951).
B. J. Marshall, I. Hislop et al, "Histological Improvement of Active Chronic Gastritis in Patients Treated with De-Nol", 14 Australia & New Zealand J. of Medicine 907 (Dec. 1984).
Antimicrobial Agents and Chemotherapy, Jul. 1980, pp. 118-121 Klin. Med. (Mosk) 59(2): 48-50 (Feb.) 1981 (translation).
Antimicrobial Agents and Chemotherapy, Apr. 1981, pp. 593-597.
Antimicrobial Agents and Chemotherapy, Oct. 1983, pp. 509-513.
Yaoxue Xuebao 19(1); 5-11, 1984 (translation).
Antimicrobial Agents and Chemotherapy, Dec. 1985, pp. 837-838; Aug. 1985, pp. 188-191.
The Journal of Infectious Diseases, vol. 153, No. 4 Apr. 1986, 650-657.
Harleston K. M.
Henley III Raymond J.
Mohl D. C.
Schaeffer J. D.
The Procter & Gamble & Company
LandOfFree
Methods and compositions for the treatment of gastrointestinal d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of gastrointestinal d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of gastrointestinal d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-959700